Epidarex Capital

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Transine Therapeutics

Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Lunac Therapeutics is a UK-based drug discovery company.

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Slate Bio is an immunotherapeutics development company that develops therapies that restore the body's natural immunological response in different diseases using bifunctional IL233 cytokine, thereby providing users with an independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics.

Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.

Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Founded in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome, a multi-protein complex involved in the body's immune response. NodThera aims to address a variety of inflammatory and neuroinflammatory diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. Through its innovative approach to inflammasome research, NodThera seeks to contribute to the advancement of therapeutic options for these conditions.

Lunac Therapeutics is a UK-based drug discovery company.

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Founded in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome, a multi-protein complex involved in the body's immune response. NodThera aims to address a variety of inflammatory and neuroinflammatory diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. Through its innovative approach to inflammasome research, NodThera seeks to contribute to the advancement of therapeutic options for these conditions.

AdoRx Therapeutics Limited is a drug discovery company based in Edinburgh, United Kingdom, focused on developing new therapeutics for cancer by modulating the adenosine pathway. Founded in 2017, the company targets the high levels of adenosine present in the tumor microenvironment, which allow cancer cells to evade the immune system. AdoRx's lead programs concentrate on creating tailored adenosine receptor antagonists designed to counteract the effects of elevated adenosine levels. The leadership team at AdoRx has extensive experience in drug discovery, having previously developed over 25 clinical candidates. The company is supported by investment from Epidarex Capital and Sixth Element Capital, enhancing its capacity to advance innovative cancer treatments.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

Eternygen GmbH is a biotechnology company based in Berlin, Germany, with an additional office in the United Kingdom. Founded in June 2012, the company specializes in the research and development of innovative drugs aimed at treating dietary-related metabolic diseases, which have seen a significant rise in prevalence over recent decades. Eternygen focuses on small molecule inhibitors targeting the sodium-coupled citrate transporter (NaCT), a crucial regulator of lipid metabolism linked to conditions such as fatty liver, diabetes, and obesity. By addressing the underlying metabolic failures associated with these diseases, Eternygen aims to develop safe and effective therapies that can enhance patient care in managing these widespread health issues.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Mironid Limited is a drug discovery company focused on developing drug candidate molecules that modulate the activity of key cell signaling proteins. Its primary aim is to create treatments for degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's drug discovery pipeline features Novel ShoLo compounds targeting chronic inflammatory diseases and Novel LoAc compounds for degenerative kidney diseases. Mironid employs a unique Physiology Mirroring Approach, which utilizes cell signaling to design assays that replicate the conformation and environment of drug targets as found in living cells. Founded in 2014, Mironid is located in Newhouse, United Kingdom.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.

Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.

Confluence Life Sciences, Inc. operates as a KINect technology based company that focuses on drug design to identify mechanistically novel drugs. It develops a portfolio of projects to address unmet medical needs in caner and chronic inflammatory diseases. The company focuses on designing and developing kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis, or in the modulation of chronic inflammation. Its KINect technology platform enables the identification and development of new protein kinase drugs. Confluence Life Sciences, Inc. was founded in 2010 and is based in Saint Louis, Missouri. As of August 3, 2017, Confluence Life Sciences, Inc. operates as a subsidiary of Aclaris Life Sciences, Inc.

Funderbeam is an innovative platform that facilitates investing and trading in equity stakes of private companies, primarily targeting early-stage investments. Founded in 2013 and headquartered in Tallinn, Estonia, with an additional office in London, Funderbeam operates as the world's first primary and secondary marketplace for early-stage investments, utilizing blockchain technology for security. The platform enables founders to raise funds while providing liquidity opportunities for early-stage equity investors. In addition to its main operations, Funderbeam also has a subsidiary based in Zagreb, Croatia, which focuses on equity crowdfunding, further expanding its reach to support investors and startups in South-East Europe.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Clyde Biosciences Ltd. specializes in developmental drug testing solutions, offering insights into the mechanisms and actions of drugs during research and development. The company develops innovative technologies such as cellOPTIQ, an optical action potential assay that helps clients understand the effects of drug compounds on human cells, specifically addressing the cardiotoxicity risk of new and existing drugs. Additionally, Clyde Biosciences offers XTENDSR, which enables direct measurements of drug-induced changes in cardiac sarcoplasmic reticulum function. Serving pharmaceutical and biotechnology companies both in the United Kingdom and internationally, Clyde Biosciences aims to meet critical needs in drug testing. Founded in 2012, the company is headquartered in Glasgow, United Kingdom.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Sirakoss Ltd. is a medical device company based in Edinburgh, United Kingdom, specializing in the development of synthetic bone graft substitutes for various applications, including trauma, spine, craniomaxillofacial, and dental procedures. Founded in 2010, the company offers products such as MaxSi graft granules and a putty system that allows surgeons to shape the graft material for direct application at the defect site. Sirakoss is recognized for its innovative approach in the medical device sector and operates as a subsidiary of OssDsign AB.

Confluence Life Sciences, Inc. operates as a KINect technology based company that focuses on drug design to identify mechanistically novel drugs. It develops a portfolio of projects to address unmet medical needs in caner and chronic inflammatory diseases. The company focuses on designing and developing kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis, or in the modulation of chronic inflammation. Its KINect technology platform enables the identification and development of new protein kinase drugs. Confluence Life Sciences, Inc. was founded in 2010 and is based in Saint Louis, Missouri. As of August 3, 2017, Confluence Life Sciences, Inc. operates as a subsidiary of Aclaris Life Sciences, Inc.

Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2014. The company specializes in optical molecular imaging technology that facilitates image-guided therapy for the detection, diagnosis, and monitoring of diseases. It focuses on the discovery and development of small molecules and peptides that can be conjugated with fluorescent dyes, allowing for real-time disease detection during interventional procedures, such as surgery. Edinburgh Molecular Imaging has raised over £15 million in non-dilutive funding from organizations like the Wellcome Trust, EPSRC, and MRC to advance its innovative SMART Agents, which enhance molecular imaging capabilities. The team behind the company comprises experienced scientists and clinicians with extensive expertise in medicinal chemistry, biochemistry, cell biology, and clinical development, positioning the company to contribute significantly to the field of medical imaging.